RT Journal Article
SR Electronic
T1 Genetically informed precision drug repurposing for lung function and implications for respiratory infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.25.20139816
DO 10.1101/2020.06.25.20139816
A1 Reay, William R.
A1 Shair, Sahar I. El
A1 Geaghan, Michael P.
A1 Riveros, Carlos
A1 Holliday, Elizabeth G.
A1 McEvoy, Mark A.
A1 Hancock, Stephen
A1 Peel, Roseanne
A1 Scott, Rodney J.
A1 Attia, John R.
A1 Cairns, Murray J.
YR 2020
UL http://medrxiv.org/content/early/2020/06/26/2020.06.25.20139816.abstract
AB Impaired lung function is associated with significant morbidity and mortality. Restrictive and obstructive lung disorders are a large contributor to decreased lung function, as well as the acute impact of infection. Measures of pulmonary function are heritable, and thus, we sought to utilise genomics to propose novel drug repurposing candidates which could improve respiratory outcomes. Lung function measures were found to be genetically correlated with metabolic and hormone traits which could be pharmacologically modulated, with a causal effect of increased fasting glucose on diminished lung function supported by latent causal variable models and Mendelian randomisation. We developed polygenic scores for lung function specifically within pathways with known drug targets to prioritise individuals who may benefit from particular drug repurposing opportunities, accompanied by transcriptome-wide association studies to identify drug-gene interactions with potential lung function increasing modes of action. These drug repurposing candidates were further considered relative to the host-viral interactome of three viruses with associated respiratory pathology (SARS-CoV2, influenza, and human adenovirus). We uncovered an enrichment amongst glycaemic pathways of human proteins which putatively interact with virally expressed SARS-CoV2 proteins, suggesting that antihyperglycaemic agents may have a positive effect both on lung function and SARS-CoV2 progression.Competing Interest StatementW.R.R and M.J.C have filed a patent related to the use of the pharmagenic enrichment score framework in complex disorders.Funding StatementThis study was supported by an NHMRC project grant (1147644). M.J.C. is supported by an NHMRC Senior Research Fellowship (1121474).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Hunter New England Human Research Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are publicly available from the references described in the manuscript. Code related to this study can be found at the following link: https://github.com/Williamreay/Lung_function_drug_repurposing_manuscript https://github.com/Williamreay/Lung_function_drug_repurposing_manuscript